Sarepta says early filing for DMD gene therapy may be back onThe development of gene therapies for Duchenne muscular dystrophy has proved to be challenging, but one of the Share XSarepta says early filing for DMD gene therapy may be back onhttps://pharmaphorum.com/news/sarepta-says-early-filing-for-dmd-gene-therapy-may-be-back-on/
Pfizer pauses Duchenne gene therapy trial after patient deathPfizer has called a halt to a clinical trial of its gene therapy for Duchenne muscular dystrophy as Share XPfizer pauses Duchenne gene therapy trial after patient deathhttps://pharmaphorum.com/news/pfizer-pauses-duchenne-gene-therapy-trial-after-patient-death/
Buoyed by new data, Santhera preps filing for DMD drug vamoroloneA year ago, Swiss biotech Santhera was slashing staff to cut costs after it abandoned lead Duchenne muscular Share XBuoyed by new data, Santhera preps filing for DMD drug vamorolonehttps://pharmaphorum.com/news/buoyed-by-new-data-santhera-preps-filing-for-dmd-drug-vamorolone/
Capricor preps phase 3 for Duchenne cell therapy as it seeks a partnerCapricor Therapeutics’ bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get Share XCapricor preps phase 3 for Duchenne cell therapy as it seeks a partnerhttps://pharmaphorum.com/news/capricor-preps-phase-3-for-duchenne-cell-therapy-as-it-seeks-a-partner/
First UK patient joins Pfizer’s phase 3 DMD gene therapy trialThe first UK patient has enrolled on Pfizer’s phase 3 trial for its Duchenne muscular dystrophy (DMD) gene Share XFirst UK patient joins Pfizer’s phase 3 DMD gene therapy trialhttps://pharmaphorum.com/news/first-uk-patient-joins-pfizers-phase-3-dmd-gene-therapy-trial/
Scotland opens door to Translarna for Duchenne muscular dystrophyA disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland Share XScotland opens door to Translarna for Duchenne muscular dystrophyhttps://pharmaphorum.com/news/scotland-opens-door-to-translarna-for-duchenne-muscular-dystrophy/
Catabasis craters after giving up on muscular dystrophy leadCatabasis has conceded defeat with its Duchenne muscular dystrophy drug edasalonexent, pulling the plug on the drug after Share XCatabasis craters after giving up on muscular dystrophy leadhttps://pharmaphorum.com/news/catabasis-craters-after-giving-up-on-muscular-dystrophy-lead/
NS Pharma takes on Sarepta as FDA approves DMD drugThe FDA has approved a new therapy for the rare muscle wasting disease Duchenne muscular dystrophy (DMD) as Share XNS Pharma takes on Sarepta as FDA approves DMD drughttps://pharmaphorum.com/news/ns-pharma-sarepta-fda-approves-dmd-drug/
Roche snaps up ex-US rights to Sarepta’s DMD gene therapyRoche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar Share XRoche snaps up ex-US rights to Sarepta’s DMD gene therapyhttps://pharmaphorum.com/news/roche-snaps-up-ex-us-rights-to-sareptas-dmd-gene-therapy/
